Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 3,743 shares at $229.99 ($873K) on 2021-09-27, disclosed to the SEC on 2021-09-29.
Open-market sale of $873k NVAX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $228.12 | 57 | $13K | 1.5% |
| 2 | $229.99 | 225 | $52K | 5.9% |
| 3 | $229.99 | 225 | $52K | 5.9% |
| 4 | $231.04 | 36 | $8K | 1.0% |
| 5 | $231.04 | 648 | $150K | 17.2% |
| 6 | $231.07 | 272 |
| $63K |
| 7.2% |
| 7 | $231.07 | 272 | $63K | 7.2% |
| 8 | $232.00 | 318 | $74K | 8.5% |
| 9 | $233.24 | 262 | $61K | 7.0% |
| 10 | $233.24 | 262 | $61K | 7.0% |
| 11 | $233.87 | 217 | $51K | 5.8% |
| 12 | $233.87 | 217 | $51K | 5.8% |
| 13 | $235.10 | 203 | $48K | 5.5% |
| 14 | $236.30 | 98 | $23K | 2.7% |
| 15 | $237.29 | 57 | $14K | 1.5% |
| 16 | $239.04 | 124 | $30K | 3.4% |
| 17 | $240.37 | 99 | $24K | 2.7% |
| 18 | $243.98 | 56 | $14K | 1.6% |
| 19 | $248.13 | 95 | $24K | 2.7% |
| Total | $233.18 avg | 3,743 | $873K | 100% |
| Filing → |
| NVAX | SELL | 2021-12-09 | $1.6M | — | Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |